Page 3 - Mind Cure News Today

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("Mind Cure" or the "Company"), a leader in developing technology to create psychedelic-related treatments, is pleased to announce the addition of Rob Hill to the Board of Directors. Mr. Hill brings over twenty years of senior leadership experience in capital markets, and specific domain expertise in heavily regulated markets experiencing hyper-growth, big data and compliance management. He has extensive management a...

Share this article Share this article Celebrated neurologist, psychiatrist and plant-medicine expert Dr. Dan Engle brings years of understanding of psychedelic medicine into research with Mind Cure. VANCOUVER, BC, Feb. 17, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( "Mind Cure" or the "Company") is pleased to announce the engagement of Dr. Dan Engle as Mind Cures Primary Investigator Consultant. Dr. Engle is Board Certified in Psychiatry and Neurology, wit...

Rise In Consumer Acceptance of Psychedelic Drug Therapies Is Quickly Increasing Financialnewsmedia.com News Commentary Share this article Share this article PALM BEACH, Fla., Feb. 17, 2021 /PRNewswire/ -- Psychedelics are making their way out of the counterculture and back into the mainstream, with research and media interest in the mind-altering substances growing substantially. Some have even called psychedelics "psychiatrys brave new world." The revitalization of psychedelics has occurred al...

Mind Cure Closes $18M Raise Mind Cure Health Inc. (CSE:MCUR) recently announced the closing of a CA$23 Million ($18.1 million) offering. The company issued approximately 38 million units, consisting of one share and one half of a share purchase warrant, at CA$0.60 per unit.  The proceeds will be used to finance product research and development, advance the company’s technological capabilities, marketing expenditures and product awareness, as well as for working capital. So far, Mind Cure ha...

Mind Cure Announces Closing of $23 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES Mind Cure Health Inc. a mental health and wellness company with a mission to identify and develop products that ease suffering, increase productivity, and enhance mental health, is pleased to announce that it has ...

Mind Cure Health Inc. Announces an Increase to Previously Announced Bought Deal Public Offering Mind Cure Health Inc. a mental health and wellness company with a mission to identify and develop products that ease suffering, increase productivity, and enhance mental health, is pleased to announce that it has entered into an amended … /THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN ...

MINDCURE Included in First Psychedelic ETF & North American Psychedelics Index News provided by Share this article Share this article Mind Cure among respected life science and therapeutic technology peers in first ever Psychedelic ETF & North American Psychedelic Index VANCOUVER, BC, Jan. 21, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( "MINDCURE" or the "Company") is pleased to announce its inclusion among 17 psychedelic companies in the first ever Psych...

Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy News provided by Share this article Share this article The strategic partnership between Mind Cure and ATMA will bridge access to research locations for psychedelic drug research while providing patient data for iSTRYM , Mind Cures digital therapeutics platform. VANCOUVER, BC, Jan. 12, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQ...

Mental Health Demand For Development Of Psychedelic Drug Therapies Is Increasing PALM BEACH, Fla., Jan. 12, 2021 /PRNewswire/ -- After being relegated to the margins of sincere scientific examination for about five decades, growing researchers and scientists are exploring the therapeutic value of psychedelic drugs and compounds that could be a new treatment option for people with depression. According to Data Bridge Market Research North America psychedelic drugs market is expected to gain mar...

Mind Cure iSTRYM (CNW Group/Mind Cure Health Inc.) "As a life sciences and digital therapeutics company, providing speed to market with novel psychedelic therapies through deeper data analytics is a strength we are developing with iSTRYM. Further, as we build out our database for mental wellness, both therapists and individuals will get mental wellness protocols for wellness optimization and support. iSTRYM exists to become the source that individuals turn to for science-backed, personalized ...